Prostate 國際重要參考文獻

作者為 TRS 會員 (依照出版年度排序)

1. Combining prostate health index and multiparametric magnetic resonance imaging in estimating the histological diameter of prostate cancer
   BMC Urol. 2021 Nov 20;21(1):161
   https://pubmed.ncbi.nlm.nih.gov/34801024/
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606059/
   　

2. IVIM Parameters on MRI Could Predict ISUP Risk Groups of Prostate Cancers on Radical Prostatectomy
   Front Oncol . 2021 Jul 1;11:659014
   https://pubmed.ncbi.nlm.nih.gov/34277409/
   https://www.frontiersin.org/articles/10.3389/fonc.2021.659014/full
   　

3. The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer
   Scientific Reports. 2021 Mar 5;11(1):1286
   https://www.nature.com/articles/s41598-020-78428-6
   　

4. Autosegmentation of Prostate Zones and Cancer Regions from Biparametric Magnetic Resonance Images by Using Deep-Learning-Based Neural Networks
   Sensors (Basel) 2021 Apr 12;21(8):2709
   https://pubmed.ncbi.nlm.nih.gov/33921451/
   https://www.mdpi.com/1424-8220/21/8/2709
   　

5. Comparison between ⁶⁸Ga-PSMA-11 PET/CT and multiparametric magnetic resonance imaging in patients with biochemically recurrent prostate cancer following robot-assisted radical prostatectomy
   J Formos Med Assoc. 2021 Jan;120(1 Pt 3):688-696
   https://pubmed.ncbi.nlm.nih.gov/32739147/
   https://linkinghub.elsevier.com/retrieve/pii/S0929-6646(20)30341-7
   　

6. Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population
   World J Urol. 2020 May;38(5):1207-1214
   https://pubmed.ncbi.nlm.nih.gov/31440806/
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190581/
   　

7. Histogram analysis of prostate cancer on dynamic contrast-enhanced magnetic resonance imaging: A preliminary study emphasizing on zonal difference
   PLoS One. 2019 Feb 12;14(2):e0212092
   https://pubmed.ncbi.nlm.nih.gov/30753222/
   https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212092
   　

8. Metabolic Volumetric Parameters in ¹¹C-Choline PET/MR Are Superior PET Imaging Biomarkers for Primary High-Risk Prostate Cancer
   Contrast Media Mol Imaging. 2018 Nov 5;2018:8945130
   https://pubmed.ncbi.nlm.nih.gov/30532664/
   https://www.hindawi.com/journals/cmmi/2018/8945130/
   　

9. Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate
   Abdom Radiol (NY). 2018 Sep;43(9):2487-2496
   https://pubmed.ncbi.nlm.nih.gov/29460041/
   https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946380/
   　

10. The Influence of Serum Prostate-Specific Antigen on the Accuracy of Magnetic Resonance Imaging Targeted Biopsy versus Saturation Biopsy in Patients with Previous Negative Biopsy
    Biomed Res Int. 2017;2017:7617148
    https://pubmed.ncbi.nlm.nih.gov/29159180/
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5660748/
    　

11. In-Bore 3-T MR-guided Transrectal Targeted Prostate Biopsy: Prostate Imaging Reporting and Data System Version 2-based Diagnostic Performance for Detection of Prostate Cancer
    Radiology. 2017 Apr;283(1):130-139
    https://pubmed.ncbi.nlm.nih.gov/27861110/
    https://pubs.rsna.org/doi/pdf/10.1148/radiol.2016152827
    　

12. ¹¹C-choline PET/MRI for Characterization of Primary High-Risk Prostate Cancer: Correlations between Positron Emission Tomography Imaging Parameters and Clinical Features
    Journal of Pharmacy and Pharmacology 7 (2017) 391-400
    https://davidpublisher.com/Public/uploads/Contribute/5959ed3729f63.pdf
    　

13. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer
    Abdom Radiol (NY). 2016 Nov;41(11):2209-2217.
    https://pubmed.ncbi.nlm.nih.gov/27364781/
    Erratum to: Abdom Radiol (NY). 2017 May;42(5):1619. doi: 10.1007/s00261-017-1047-1.
    https://link.springer.com/article/10.1007/s00261-017-1047-1
    　

14. Cognitive MRI-TRUS Fusion Targeted Prostate Biopsy According to PI-RADS Classification in Patients with Prior Negative Systematic Biopsy Results
    J Chin Med Assoc. 2016 Nov; 79(11):618-624
    https://pubmed.ncbi.nlm.nih.gov/27567440/
    　

15. Multiparametric MRI of the prostate: diagnostic performance and interreader agreement of two scoring systems
    Br J Radiol. June 2016; 89(1062): 20151056
    https://pubmed.ncbi.nlm.nih.gov/27007818/
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5258169/
    　

16. REST modulates hypoxia-induced neuroendocrine differentiation of prostate cancer cells by activating autophagy signaling
    Oncotarget. 2016 May 3;7(18):26137-51
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041970/
    　

17. Magnetic Resonance Imaging of Seminal Vesicle Cyst Associated with Ipsilateral Urinary Anomalies
    J Formos Med Assoc 2006;105(2):125–131
    https://www.sciencedirect.com/science/article/pii/S0929664609603338
    　

作者為非 TRS 會員 (依照出版年度排序)

1. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for ¹⁸F-fluciclovine-PET/CT in delineating sites of recurrence and identifying patients with oligometastatic disease
   Urol Oncol. 2021 Jun;39(6):365.e9-365.e16.
   https://pubmed.ncbi.nlm.nih.gov/33160848/
   https://linkinghub.elsevier.com/retrieve/pii/S1078143920304890
   　

2. ¹⁸F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial
   Lancet 2021; 397: 1895–904
   https://linkinghub.elsevier.com/retrieve/pii/S014067362100581X
   　

3. The Diagnostic Performance of the Length of Tumor Capsular Contact on MRI for Detecting Prostate Cancer Extraprostatic Extension: A Systematic Review and Meta-Analysis
   Korean J Radiol 2020;21(6):684-694
   https://pubmed.ncbi.nlm.nih.gov/32410407/
   https://doi.org/10.3348/kjr.2019.0842
   　

4. Can Extraprostatic Extension Be Predicted by Tumor-Capsule Contact Length in Prostate Cancer? Relationship With International Society of Urological Pathology Grade Groups
   AJR 2020; 214:588–596
   https://pubmed.ncbi.nlm.nih.gov/31670596/
   https://www.ajronline.org/doi/10.2214/AJR.19.21828
   　

5. Extraprostatic Tumor Extension: Comparison of Preoperative Multiparametric MRI Criteria and Histopathologic Correlation after Radical Prostatectomy
   Radiology 2020; 296:87–95
   https://pubs.rsna.org/doi/10.1148/radiol.2020192133
   　

6. ¹⁸F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis
   Cancers 2019, 11, 1348
   https://www.mdpi.com/2072-6694/11/9/1348
   　

7. Review of ¹⁸F-Fluciclovine PET for Detection of Recurrent Prostate Cancer
   RadioGraphics 2019; 39:822-841
   https://pubs.rsna.org/doi/10.1148/rg.2019180139
   　

8. Update on ¹⁸F-Fluciclovine PET for Prostate Cancer Imaging
   J Nucl Med. 2018 May;59(5):733-739
   https://pubmed.ncbi.nlm.nih.gov/29523631/
   　

9. A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI
   Radiology 2019; 290:709–719
   https://pubs.rsna.org/doi/10.1148/radiol.2018181278
   　

10. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer
    Radiology. 2018 Aug;288(2):495-505
    https://pubmed.ncbi.nlm.nih.gov/29786490/
    　

11. ¹⁸F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients
    European Radiology (2018) 28:3151–3159
    https://link.springer.com/article/10.1007/s00330-017-5213-1
    　

12. Prospective head-to-head comparison of ¹¹C-choline-PET/MR and ¹¹C-choline-PET/CT for restaging of biochemical recurrent prostate cancer
    Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2179-2188
    https://pubmed.ncbi.nlm.nih.gov/28803358/
    　

13. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68 Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI
    Eur J Nucl Med Mol Imaging. 2017 May;44(5):776-787
    https://pubmed.ncbi.nlm.nih.gov/27988802/
    　

14. Diagnostic Value of Integrated PET/MRI for Detection and Localization of Prostate Cancer: Comparative Study of Multiparametric MRI and PET/CT
    J Magn Reson Imaging. 2017 Feb;45(2):597-609
    https://pubmed.ncbi.nlm.nih.gov/27586519/
    　

15. Evaluation of Prostate Cancer with PET/MRI
    J Nucl Med. 2016 Oct;57(Suppl 3):111S-116S
    https://pubmed.ncbi.nlm.nih.gov/27694163/
    　

16. Evaluation of the PET component of simultaneous [¹⁸F] choline PET/MRI in prostate cancer: comparison with [¹⁸F] choline PET/CT
    Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):79-88
    https://pubmed.ncbi.nlm.nih.gov/24085502/
    　

17. PET/MR in prostate cancer: technical aspects and potential diagnostic value
    Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S79-88
    https://pubmed.ncbi.nlm.nih.gov/23703457/
    　

18. Combining prostrate-specific antigen and Gleason score increases the diagnostic power of endorectal coil magnetic resonance imaging in prostate cancer pathological stage
    J Chin Med Assoc. 2013 Jan;76(1):20-4
    https://pubmed.ncbi.nlm.nih.gov/23331777/
    https://journals.lww.com/jcma/Fulltext/2013/01000/Combining_prostrate_specific_antigen_and_Gleason.4.aspx